CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications


Eligible Medicare beneficiaries may now get certain GLP-1 medications for $50 per month through the Medicare GLP-1 Bridge, a new Centers for Medicare & Medicaid Services (CMS) initiative designed to expand access to innovative treatments and test the impacts of increased access to GLP-1 drugs for weight management on the Medicare program. 

Through the Medicare GLP-1 Bridge, eligible individuals enrolled in Medicare Part D prescription drug coverage can obtain certain GLP-1 medications to lose weight or maintain weight reduction at a predictable and affordable cost of $50 per month. The initiative will remain available through December 31, 2027, and reflects CMS’ continued focus on improving access to innovative treatments that support better long-term health outcomes.

“For too long, many Americans have been unable to access these treatments because of cost,” said CMS Administrator Dr. Mehmet Oz. “The Medicare GLP-1 Bridge creates a new pathway for eligible beneficiaries to afford GLP-1 medications. If you think a GLP-1 medication may be right for you, talk with your doctor and learn whether you qualify.”

Medicare beneficiaries interested in learning whether they qualify for the Medicare GLP-1 Bridge should visit Medicare.gov/glp1bridge and talk with their doctor about whether a GLP-1 medication may be right for them.

Not all Medicare beneficiaries will qualify for the Medicare GLP-1 Bridge, including individuals who already receive GLP-1 medications through their existing Medicare prescription drug coverage or are eligible for GLP-1 coverage through the Medicare Part D benefit. 

CMS also has released resources for prescribers and pharmacies to support Medicare GLP-1 Bridge implementation. These materials, along with eligibility information and details about the initiative, are available at https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge

The Medicare GLP-1 Bridge builds on CMS’ broader efforts to improve access to innovative therapies and support healthier outcomes for Medicare beneficiaries.

This news release was published by the Centers for Medicare & Medicaid Services on July 1, 2026.




Source link

Hot this week

Understanding Bipolar Disorder | Andrew Huberman #shorts #andrewhuberman #neuroscience

Understanding Bipolar Disorder | Andrew Huberman #hubermanlab #neuroscience #shorts...

Cheesy Chicken Casserole

Cheesy Chicken Casserole is a family-friendly meal loaded...

Should You Supplement with Vitamin K2?

Vitamin K supplements are touted for bone, brain,...

This is not raisins…stop beingstupid..#drrobin #facts #health #food #ayurved #doctor #remedy

This is not raisins...stop beingstupid..#drrobin #facts #health #food #ayurved...

What Your Eyes May Reveal About Your Brain Health Years Ahead

More than 7 million Americans are now living...

Topics

Understanding Bipolar Disorder | Andrew Huberman #shorts #andrewhuberman #neuroscience

Understanding Bipolar Disorder | Andrew Huberman #hubermanlab #neuroscience #shorts...

Cheesy Chicken Casserole

Cheesy Chicken Casserole is a family-friendly meal loaded...

Should You Supplement with Vitamin K2?

Vitamin K supplements are touted for bone, brain,...

This is not raisins…stop beingstupid..#drrobin #facts #health #food #ayurved #doctor #remedy

This is not raisins...stop beingstupid..#drrobin #facts #health #food #ayurved...

What Your Eyes May Reveal About Your Brain Health Years Ahead

More than 7 million Americans are now living...

Summer Sinusitis: Why Your Congestion Won’t Go Away

If your sinus infections seem to show up...

How We Finally Got the Active Ingredient Where It Belongs

In the first article, I laid out the...

Related Articles

Popular Categories

\